T-cell ProLymphocytic Leukaemia (T-PLL) is the most aggressive of all known forms of leukaemia. Although many cancer drugs are now available, therapeutic success is limited for T-PLL patients. Hitherto, no international studies have been conducted and stand-alone studies are hardly comparable with each other, since they use different diagnostic and treatment response assessment criteria. Haemato-oncologist Philipp Staber from MedUni Vienna's Division of Hematology and Hemostaseology and member of the Comprehensive Cancer Center Vienna (CCC), instigated an international expert group, which has now produced the first ever binding consensus paper. This creates the basis for all further research into T-PLL. These consensus criteria have now been published as the lead article in top journal "Blood".
T-cell prolymphocytic leukaemia (T-PLL) is the most aggressive of all known forms of leukaemia and develops from degenerate mature T-cells. However, it is very rare and is regarded as an "orphan disease" (rare disease). Every year, there are around 40 new cases in Austria, predominantly in patients over the age of sixty.
In 2017, a team of researchers led by haemato-oncologist Philipp Staber from MedUni Vienna's Division of Hematology and Hemastaseology identified the bcl2-inhibitor venetoclax as a promising form of treatment. However, up until now, there was no international agreement as to what exactly constitutes T-PLL, how this complex disease should be diagnosed or how to stage it or assess treatment response.
Although stand-alone studies had been done, the results did not allow any international comparison to be made, since they used very different criteria for diagnosis and assessing treatment response in T-PLL. Up until now, it was not clear precisely when leukaemia is T-PLL, that is to say what methods should be used to diagnose it to distinguish it from other similar diseases. There was a similar lack of uniformity in the criteria used for assessing treatment response. As a consequence of this, advances in treatment have so far been unsatisfactory.
At Staber's instigation, a study group of international experts was set up to draft a recently completed consensus paper, which, in future, will form the basis for an internationally standardised procedure for diagnosing and assessing treatment response. "This work represents a milestone in the study of T-PLL", emphasises Staber. "We now have a basis for the scientific study of T-PLL. This is the scientific birth of T-cell prolymphocytic leukaemia, as it were, so that we can finally find effective treatments for our T-PLL patients."
This consensus paper has now facilitated the first clinical study, which started in September 2019 and will run in 20 countries, to accurately document the therapeutic effect of the drug venetoclax. Staber is the coordinating Principal Investigator of this study. These developments create the necessary preconditions to finally allow comprehensive investigation of the clinical picture of T-PLL and to develop new therapeutic approaches.
"Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL)". Philipp B. Staber, Marco Herling, Mar Bellido, Eric D. Jacobsen, Matthew S. Davids, Tapan Mahendra Kadia, Andrei Shustov, Olivier Tournilhac, Emmanuel Bachy, Francesco Zaja, Kimmo Porkka, Gregor Hoermann, Ingrid Simonitsch, Claudia Haferlach, Stefan Kubicek, Marius Mayerhoefer, Georg Hopfinger, Ulrich Jaeger and Claire Dearden. Blood 2019 :blood.2019000402; doi.org/10.1182/blood.2019000402